> ## Content Index
> Fetch the complete content index at: https://www.fdaweb.com/llms.txt
> Use this file to discover other available public pages before exploring further.

# Joint Advisory Panel to Meet on Pain Drug NDA
- URL: https://www.fdaweb.com/joint-advisory-panel-to-meet-on-pain-drug-nda/
- Published: 2018-03-30T12:00:00.000Z
- Updated: 2026-09-14T23:56:18.000Z
- Author: David McFarland
- Tags: FDA Policy/General, #legacy-id-D5141107

*Federal Register* notice: FDA has announced a 5/22 joint Anesthetic and Analgesic Drug Products Advisory Committee and Drug Safety and Risk Management Advisory Committee advisory committee meeting. Panel members are scheduled to discuss an Insys Development NDA for buprenorphine sublingual spray, indicated for treating moderate-to-severe acute pain where the use of an opioid analgesic is appropriate. To view the notice, click [here](https://www.gpo.gov/fdsys/pkg/FR-2018-03-29/pdf/2018-06307.pdf?ref=fdaweb.com).